Where ends the TRAIL in arthritis?

Michael Hahne

doi:10.4081/rr.2009.e10

Where ends the TRAIL in arthritis?

https://doi.org/10.4081/rr.2009.e10

PDF HTML

Vol. 1 No. 1 (2009)

Submitted: 8 June 2009
Accepted: 14 October 2009

Published: 27 October 2009

Rheumatoid arthritis, TRAIL, TNF family

Abstract Views: 779

PDF: 302
HTML: 1950

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Michael Hahne
michael.hahne@igmm.cnrs.fr
CNRS, Germany.

A hallmark of rheumatoid arthritis (RA) is the pseudo-tumoral expansion of fibroblast-like synoviocytes (FLS), as these cells invade and finally destroy the joint structure. RA FLS have been proposed therefore as a therapeutic target. The TNF-related apoptosis-inducing ligand (TRAIL) has gained much attention as a possible therapeutic reagent for the treatment of tumors, as TRAIL was described originally to induce apoptosis specifically in cancer cells but not in normal cells. The fact that FLS in RA patients exhibit tumor-like features led to investigations on the effect of TRAIL on ex-vivo RA FLS. In this review we aim to summarize what is presently known on the role of TRAIL in RA.

Supporting Agencies

INSERM, ARC (Association pour la Recherche sur le Cancer), société Française de Rhumatologie (SFR), ANR (Agence Nationale de la Recherche), European Community

Hahne, M. (2009). Where ends the TRAIL in arthritis?. Rheumatology Reports, 1(1), e10. https://doi.org/10.4081/rr.2009.e10